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Predominant expression of Alzheimer’s
disease-associated BIN1 in mature
oligodendrocytes and localization to
white matter tracts
Pierre De Rossi1†, Virginie Buggia-Prévot1†, Benjamin L. L. Clayton2, Jared B. Vasquez3, Carson van Sanford3,
Robert J. Andrew1, Ruben Lesnick1, Alexandra Botté1, Carole Deyts1, Someya Salem1, Eshaan Rao1, Richard C. Rice1,
Angèle Parent1, Satyabrata Kar4, Brian Popko2, Peter Pytel5, Steven Estus3 and Gopal Thinakaran1,2,5*

Abstract
Background: Genome-wide association studies have identified BIN1 within the second most significant susceptibility
locus in late-onset Alzheimer’s disease (AD). BIN1 undergoes complex alternative splicing to generate multiple isoforms
with diverse functions in multiple cellular processes including endocytosis and membrane remodeling. An increase in
BIN1 expression in AD and an interaction between BIN1 and Tau have been reported. However, disparate descriptions
of BIN1 expression and localization in the brain previously reported in the literature and the lack of clarity on brain BIN1
isoforms present formidable challenges to our understanding of how genetic variants in BIN1 increase the risk for AD.
Methods: In this study, we analyzed BIN1 mRNA and protein levels in human brain samples from individuals with or
without AD. In addition, we characterized the BIN1 expression and isoform diversity in human and rodent tissue by
immunohistochemistry and immunoblotting using a panel of BIN1 antibodies.
Results: Here, we report on BIN1 isoform diversity in the human brain and document alterations in the levels of select
BIN1 isoforms in individuals with AD. In addition, we report striking BIN1 localization to white matter tracts in rodent
and the human brain, and document that the large majority of BIN1 is expressed in mature oligodendrocytes whereas
neuronal BIN1 represents a minor fraction. This predominant non-neuronal BIN1 localization contrasts with the strict
neuronal expression and presynaptic localization of the BIN1 paralog, Amphiphysin 1. We also observe upregulation of
BIN1 at the onset of postnatal myelination in the brain and during differentiation of cultured oligodendrocytes. Finally,
we document that the loss of BIN1 significantly correlates with the extent of demyelination in multiple sclerosis lesions.
Conclusion: Our study provides new insights into the brain distribution and cellular expression of an important risk
factor associated with late-onset AD. We propose that efforts to define how genetic variants in BIN1 elevate the risk for
AD would behoove to consider BIN1 function in the context of its main expression in mature oligodendrocytes and
the potential for a role of BIN1 in the membrane remodeling that accompanies the process of myelination.
Keywords: Alzheimer’s disease, Oligodendrocyte, BIN1, Amphiphysin 1, Multiple sclerosis, Late-onset Alzheimer’s disease,
Isoform diversity, Alternative splicing, Myelination, Immunohistochemistry
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Background
The Bridging INtegrator-1 (BIN1; also referred to as
amphiphysin II and SH3P9) is a member of the Bin/
Amphiphysin/Rvs (BAR) family of adaptor proteins that
regulates membrane dynamics in a variety of cellular
functions [1]. BIN1 was first identified as a protein
that interacted with the N-terminus of the MYC
oncoprotein [2], and cloned based on sequence similarity to Amphiphysin 1, a protein predominantly expressed in the brain [3–8]. Based on sequence similarity
to Amphiphysin 1, it has been proposed that BIN1 might
function in synaptic vesicle endocytosis [9]. However,
neuronal cultures prepared from Bin1−/− mice failed to
reveal a deficiency in basal synaptic vesicle uptake [10],
raising the possibility that BIN1 and Amphiphysin 1 may
have divergent functions in the brain. Unlike its close
paralog Amphiphysin 1, BIN1 is broadly expressed in several tissues, with the highest expression in skeletal muscle
[2, 4, 6, 11]. Alternate splicing of the 20 exons in BIN1
gene generates at least 10 transcripts encoding ubiquitous
and tissue-specific isoforms, which differ not only in their
tissue distribution but also in subcellular localization and
cellular function [2, 4–6, 12, 13].
All isoforms of BIN1 contain an N-terminal BAR domain, which functions in sensing and generating membrane curvature and is critical for BIN1 function in
membrane tubulation and budding/vesicle formation. A
C-terminal SH3 domain, also found in all isoforms,
mediates BIN1 interaction with proteins involved in
endocytosis, such as dynamin, synaptojanin, and endophilin [1, 4–6, 14]. The CLathrin-Associated Protein
binding region (CLAP domain), encoded by alternatively
spliced exons present only in the neuronal BIN1 isoforms,
is important for BIN1’s function in clathrin-mediated
endocytosis and synaptic vesicle recycling [1, 9]. Crystal
structure and functional studies predicted that the BIN1
CLAP domain is critical to recruiting dynamin and regulate its self-assembly at the clathrin-coated pit [15]. Moreover, the residues encoded by the alternatively spliced
exon 7 within the BAR domain promotes BIN1 interaction
with dynamin 2 [16, 17]. In addition to proteins involved
in endocytosis, the BIN1 SH3 domain can interact with a
number of other proteins including the tyrosine kinase
c-Abl, the actin nucleation-promoting factor N-WASP,
actin, myosin, and Tau, suggesting the involvement of
the cytoskeleton in BIN1 function [18–21].
Very little is known about BIN1 expression in the brain.
The identification of polymorphisms upstream of BIN1
that act as a major genetic risk factor for late-onset AD
has stimulated an interest in understanding BIN1’s role in
the central nervous system [22–24]. It is notable that
BIN1 is ranked in the AlzGene database as the second
most statistically significant AD susceptibility gene based
on a meta-analysis [25]. In vitro assays and analysis of
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mutant flies lacking the expression of the Drosophila
BIN1 ortholog Amphiphysin have suggested that BIN1
modifies AD risk through Tau pathology [26] or β-amyloid
production [27] and studies have reported altered expression of BIN1 in Alzheimer Disease, albeit with discrepancies [26, 28–31]. Nevertheless, since functional BIN1
variants are yet to be identified, the precise link between
BIN1 and the susceptibility to AD remains elusive. A survey of the published literature reveals conflicting information on the cellular and subcellular localization of BIN1 in
the brain. Previous studies have described the presence of
BIN1 in apical dendrites, initial axon segments, along the
axons, nerve terminals, or the nodes of Ranvier [4, 26, 30].
Although it has been generally assumed that BIN1 is
mainly expressed in neurons, Bin1 was found among the
top 50 highly expressed genes in cultured oligodendrocytes
by genomic analysis [32]. A precise description of its expression and localization in the nervous system is a prerequisite for understanding BIN1 function and dysfunction
in the brain. Here, we report the prominent non-neuronal
expression of BIN1 in mouse and the human brain, which
contrasts with neuronal expression of Amphiphysin 1. We
detail BIN1 expression in mature oligodendrocytes and its
enrichment in the white matter and characterize BIN1 isoform diversity in the gray and white matter of individuals
with and without AD. The upregulation of BIN1 during in
vitro oligodendrocyte maturation and the period of myelination in vivo, and the loss of BIN1 within brain lesions of
patients with multiple sclerosis are all consistent and point
to a potential role for BIN1 in mature oligodendrocytes in
the brain.

Methods
Human autopsy tissue

The RNA analyses were performed on human anterior
cingulate brain tissue samples, which were supplied by the
University of Kentucky AD Center Neuropathology Core.
These samples have been previously described [33–35].
Evaluation of AD status was conducted by the AD Center
Neuropathology and Clinical Cores using guidelines set
forth by the National Institute on Aging Reagan Institute
that included evaluation of neurofibrillary tangles and
neuritic senile plaques [36–38]. Age at death for the
cognitively intact, i.e. non-AD donors, was 82.3 ± 8.6
(mean ± SD, n = 29) while AD donors were 81.7 ± 6.3
(mean ± SD, n = 28). The post-mortem interval for non-AD
and AD donors was 2.8 ± 0.9 and 3.4 ± 0.6 h, respectively.
The samples used for immunoblotting and immunohistochemistry were obtained from the University of Chicago
autopsy archives and NIH Neurobiobank (Table 1).
Primary cultures

Greater than 95% pure cultures of rat oligodendrocyte
progenitor cells (OPCs) were isolated from cortices of
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Table 1 List of human samples used for immunohistochemistry
and immunoblot analysisa
Patient ID

Disease

Age

Gender

PMI (h)

10152

Control

68

F

19

121405

Control

76

M

22

61220

Control

70

F

18

91412

Control

76

M

8

41524

Control

79

F

14

41522

Control

44

M

40

15109

Control

68

F

13

51501

Control

59

F

23

4320

Control

87

F

9

4064

Control

75

F

15

4294

Control

80

M

19

4307

Control

84

M

12

4308

Control

70

M

12

121115

MS

66

F

24

90712

MS

69

M

22

120213

MS

53

F

25

10618

MS

38

F

24

40317

MS

75

F

23

71202

AD; Braak 5

88

F

40

101208

AD; Braak 5

93

F

41

4279

AD Braak 5

76

M

14

4313

AD Braak 5

66

F

16

4414

AD Braak 5

69

F

15

4454

AD Braak 2-3

82

M

9

4466

AD Braak 5

81

M

16

a

AD (n = 29) and non-AD (n = 28) human samples used for qPCR analysis have
been previously described (Cited Ref: [19, 32, 68])
PMI post mortem interval

6–7 day old pups as described by sequential immunopanning on dishes coated with antibodies against Ran-2,
GalC, and O4 [39]. Ran-2−, GalC−, O4+ OPCs were
cultured in medium supplemented with the mitogen
PDGFα (Peprotech). Mature oligodendrocytes were generated by differentiating OPCs in medium containing
the hormone 3-3’-5-Triiodo-L-thyronine (Sigma). Primary rat hippocampal neurons and astrocytes were cultured as described [40].

junctional antisense primer, 5’-GCTTTCTCAAGCAGC
GAGAC-3’, corresponding to the last 6 nucleotides of
exon 6 and the first 11 nucleotides of exon 8. Each 20 μL
reaction mixture contained 20 ng of cDNA, 1 μM of each
primer, and 2X SYBR Green (Quanta Biosciences) and
was subjected to a PCR profile of 40 cycles at 95 °C for
15 sec, 60 °C for 30 sec, and 72 °C for 20 sec. A melting
curve was performed after each qPCR run to ensure specific amplification. The BIN1 isoform copy number in
samples was determined by using a standard curve generated in parallel. Copy numbers were normalized to the
geometric mean of reference genes EIF4H and RPL32.
Levels of cell type-specific genes were determined similarly. Primer sequences for microglial and endothelial cells
were reported previously [41, 42]. Additional primer
sequences were as follows: SYP (synaptophysin), 5’-AGG
GAACACATGCAAGGAG-3’ and 5’-CCTTAAACACGA
ACCACAGG-3’; MBP, 5’-AAGGCCAGAGACCAGGAT
TT-3’, and 5’-TAGCCATGGGTGATCCAGA-3’; GFAP 5’AAGAGATCCGCACGCAGTAT-3’ and 5’-GTAGTCGT
TGGCTTCGTGCT-3’. Assays were repeated at least two
times. The extent that BIN1 mRNA levels were associated
with AD-status or cell type-specific gene expression was
determined by using a general linear model (SPSS v.19).
BIN1 alternate splicing in RNA isolated from human
anterior cingulate samples was determined by PCR.
Assays included an exon 12 sense primer 5’-GAGT
CAACCACGAGCCAGAG-3’ and exon 18 antisense primer 5’-GAAGGTCTCCACCACGACAG-3’. Each 20 μL
reaction mixture contained 20 ng of cDNA, 1 μM of
each primer, and Platinum Taq (Life Technologies) and
was subjected to a PCR profile of 30 cycles at 95 °C for
15 sec, 59 °C for 30 sec, and 72 °C for 20 sec. Assays
were performed in triplicate and PCR amplicons were
excised from gels and sequenced.
Immunofluorescence labeling of transfected cells

HEK293 cells cultured on glass coverslips were transiently transfected with an expression plasmid that encodes FLAG-tagged human BIN1 isoform 7 (lacking
exons 7, 11, 13–15) [generously provided by Dr. Zhou,
Merck Research Laboratories]. The following day, the
cells were fixed, permeabilized, and stained with mAb
against FLAG or BIN1 antibodies as described [43].
Human brain immunohistochemistry

Analysis of gene expression

The expression levels of BIN1 isoforms that lack exon 7
(Delta-7-BIN1 (D7-BIN1) or include exon 7 (BIN1 + Ex7)
were determined by quantitative polymerase chain reactions (qPCR). The primers for BIN1 + Ex7 were: exon 5
sense 5’-CCTGCTGTGGATGGATTACC-3’ and exon 7
antisense 5’-GCTTTCTCAAGCAGCGAGAC-3’. D7-BIN1
reactions used the same exon 5 sense primer and a

5 μm-thick paraffin embedded brain sections from individuals with and without multiple sclerosis were rehydrated, treated with antigen retrieval buffer (DAKO) in a
steamer for 20 min, followed by a 5 min incubation with
3% H2O2 and permeabilized with PBST (phosphate-buffered saline containing 0.025% Triton-X 100). Sections
were blocked with 10% normal rabbit serum-PBST for
1 h and then incubated with the indicated primary
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antibodies (Additional file 1: Table S1) for 1 h followed
by species-specific secondary antibodies. The antigenantibody reactions were detected by Envision + kit (Dako)
or Vectastain Elite-kit (Vector laboratories). Nuclei were
counterstained using hematoxylin. The slides were
scanned using CRi Pannoramic Scan Whole Slide Scanner
and analyzed by Pannoramic Viewer (3DHISTECH).
Immunofluorescence labeling and analysis

Wild-type C57/BL6 mice (between 1-month and 5month-old) or adult rats were fixed by perfusion with
4% paraformaldehyde containing 4% sucrose. Immunofluorescence labeling was performed on 40 μm-thick
sections. Floating brain sections were subjected to epitope
retrieval by incubation in 10 mM trisodium citrate pH 6
and 0.05% Tween20 for 30 min at 90°C prior to blocking.
The sections were sequentially incubated with the indicated primary antibodies (Additional file 1: Table S1) and
Alexa Fluor-conjugated secondary antibodies (Molecular
Probes) diluted in Tris-buffered saline containing 1% BSA
and 0.25% Triton-X 100, for 48 h and 2 h, respectively.
Nuclei were labeled using Hoechst stain (Molecular
Probes) before mounting the sections on slides. Confocal
images were acquired on a Leica SP5 II STED-CW
Superresolution Laser Scanning Confocal microscope and
analyzed by ImageJ [44].
Immunoblot analysis

Frontal cortex and deep frontal white matter regions
were weighed and homogenized (20% weight/volume) in
ice-cold lysis buffer [150 mM NaCl, 50 mM Tris–HCl
pH 7.4, 0.5% NP-40, 0.5% sodium deoxycholate, 5 mM
EDTA, 0.25 mM PMSF and protease inhibitor cocktail
(Sigma)]. An equal volume of lysis buffer containing 2%
SDS was then added to each sample and briefly sonicated. Cultured cells were lysed in 150 mM NaCl,
50 mM Tris pH 7.5, 1 mM EDTA, 1% Triton-X 100,
0.5% sodium deoxycholate, 0.1% SDS. Aliquots of lysates
were fractionated by 10% or 4-20% polyacrylamide gel
electrophoresis. Primary antibodies used for Western
blot analysis are listed in Additional file 1: Table S1.
After incubation with infrared dye-conjugated secondary
antibodies, signals were recorded by the Odyssey infrared imaging system (LI-COR Biosciences) and quantified
using ImageJ [44].

Results
Differential expression of BIN1 isoforms in the gray and
white matter

We performed qPCR assays to quantify BIN1 expression
in non-AD and AD anterior cingulate brain tissue
samples. Since the inclusion of exon 7 is suggested to
vary by cell type [45], we used primers specific for BIN1
isoforms that contained exon 7 (BIN1 + Ex7) and lacked
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exon 7 [Delta-7-BIN1 (D7-BIN1)]. Sample results were
compared to standard curves for each isoform that were
analyzed in parallel to determine absolute BIN1 copy
numbers. We found that BIN1 was expressed at moderate abundance with 2,000-30,000 copies per ~20 ng
cDNA. These values were normalized relative to the
geometric mean of two housekeeping genes, ribosomal
protein L32 (RPL32) and eukaryotic initiation factor 4H
(EIF4H). The percentage of BIN1 expressed as the D7BIN1 isoform was 62 ± 15% (mean ± SD, range 23-93%,
n = 57). We observed that the expression of BIN1 + Ex7
and D7-BIN1 was not correlated (Fig. 1a). We interpret
this result as suggesting that the isoforms are either not
expressed coordinately or that they are expressed in different cell types with the proportion of these cell types
varying among samples.
To investigate this question, the expression of BIN1 + Ex7
and D7-BIN1 was compared to that of genes with celltype specific expression. Inspection of the results suggested that BIN1 + Ex7 expression was associated positively with synaptophysin expression (neuronal marker)
but not with the markers of oligodendrocytes, astrocytes,
microglia, or endothelial cells (Fig. 1c and d, Additional
file 2: Figure S1A-C). This association was confirmed
statistically by evaluating with a general linear model that
included BIN1 + Ex7 as the dependent variable and synaptophysin and AD as independent variables. This produced
a moderately significant model (adjusted R2 = 0.264).
BIN1 + Ex7 was significantly associated with synaptophysin (p = 1.07X10−4) and modestly with AD (p = 0.046, note
the limited power of 0.517) (Fig. 1c and Additional file 3:
Table S2). If the model was expanded to include the
AD-associated BIN1 single-nucleotide polymorphism
rs7561528 [46], the BIN1 + Ex7 association with synaptophysin was unchanged. However, rs7561528 was not associated with BIN1 + Ex7 expression (p = 0.3) and including
the single-nucleotide polymorphism in the model pushed
AD from significance (p = 0.068) (data not shown). The
increase in BIN1 + Ex7 expression in AD appears to be a
fairly modest 18% (Additional file 4: Table S3). These
results are in accordance with the findings reported by
Chapuis et al. where the data were normalized to either
actin or an apparent microglia gene, GUSB [26].
In contrast to BIN1 + Ex7, inspection of the graphs of
the D7-BIN1 isoform relative to cell-specific mRNAs
suggested that the D7-BIN1 isoform was associated
positively with myelin basic protein (MBP), a marker for
mature oligodendrocytes and the white matter (Fig. 1e
and f ) but not with other cell types (Additional 2:
Figure S1D–F). We confirmed this notion by qPCR analysis of RNA isolated from gray matter and white matter
and found that ~90% of BIN1 in the white matter corresponds to D7-BIN1 isoforms (Fig. 1b). Using a linear
model that included MBP and AD status, we found a
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Fig. 1 Quantification of BIN1 transcript levels in brains with and without AD. a Scatter plot of the normalized levels of BIN1 isoforms generated by
alternative splicing of exon 7 in each sample (quantified by qPCR analysis) reveals a lack of correlation between D7 + Ex7 and D7-BIN1 expression.
b qPCR analysis of BIN1 exon 7 alternative splicing in the human brain shows a significantly higher proportion of BIN1 transcripts lacking exon 7 in
white matter (WM) as compared with gray matter (GM). c–f Scatter plots of BIN1 + Ex7 and D7-BIN1 expression compared to SYP (synaptophysin)
and MBP expression. AD = AD; Norm = normalized expression. The indicated R2 values (A, C-F) are adjusted R2 values, reflecting the presence of two
independent variables in the analysis, i.e., AD status and BIN1, SYP or MBP expression

significant model (R2 = 0.553) wherein D7-BIN1 was significantly associated with MBP (p = 2.97X10−11). However,
we observed no significant association between AD and
D7-BIN1 expression (p = 0.4) (Additional file 5: Table S4).
Additional analyses did not find a significant association
between D7-BIN1 and the AD-associated single-nucleotide
polymorphism (p = 0.6). These results reveal that the association between BIN1 expression and AD status is more
complicated than previously understood due to the
expression of alternatively spliced BIN1 transcripts, and
raise the possibility that BIN1 expression may not be
limited to neurons.
BIN1 is enriched in the human brain white matter

To confirm the above results, we performed immunoblots of homogenates prepared from human brain white
matter and gray matter tissue using antibodies raised
against non-overlapping epitopes of BIN1: rabbit polyclonal antibody (pAb) BSH3 raised against epitopes

encoded by exons 17–20 (reacts with all BIN1 isoforms;
Additional file 6: Figure S2); monoclonal antibody
(mAb) 2 F11, raised against a junctional epitope generated by the juxtaposition of residues encoded by exons 6
and 8 (thus specific for D7-BIN1 isoforms) [13]; and
mAb 99D, raised against an epitope encoded by exon 17
within the Myc-binding domain [47] (Fig. 2a). The specificities of the two BIN1 mAbs have been well established
[10, 13, 47] and confirmed by transfection studies in
HEK293 cells using BIN1 isoform 7 [which lacks the exon
7-encoded sequences] (Additional file 6: Figure 2SC).
Cell-specific marker proteins expected to be enriched in
the gray matter (post-synaptic density protein 95 [PSD95]
and synaptophysin) and the white matter (MBP and aspartoacylase [ASPA]) were used to assess the purity of the
samples (Fig. 2b). Immunoblot analysis revealed two primary BIN isoforms in the gray matter, migrating at ~90
and ~65 kDa (Fig. 2c). The longest BIN1 isoform was
detected at low levels by pAb BSH3 (which can detect all
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Fig. 2 Immunoblot and RT-PCR analysis of BIN1 isoform diversity in the human brain. a The schematic structure of BIN1 indicating the epitopes
of the antibodies used in this study. b Immunoblot analysis of neuronal and oligodendrocyte marker protein levels in extracts prepared from the
human brain gray matter and white matter. c Immunoblot analysis of BIN1 and Amphiphysin 1 levels. The pAb BSH3 reacts with all BIN1 isoforms
whereas mAb 2 F11 and 99D react with D7-BIN1 and + exon 17 BIN1 isoforms, respectively. The asterisks indicate non-specific signals. d The signal
intensities of BIN1 were quantified using the Li-COR system, normalized to actin and plotted as mean ± SEM (n = 8). Statistical significance was
assessed by ANOVA. e Schematic illustration of the alternatively spliced human brain BIN1 isoforms identified in this study. Five independent
human brain samples were subjected to RT-PCR analysis by using primers corresponding to sequences within exons 12 and 18 and the resulting
amplicons were fractionated by electrophoresis. The bands were excised and individually sequenced to identify the major isoforms generated
by alternate splicing of exons 13–17. The exclusion of BIN1 exon 11 in brain and inclusion of exon 7 in isoforms 1 and 3 were inferred from the
published literature and the RT-PCR and immunoblot results of our study

isoforms) only in the gray matter. Based on its detection
by 99D (detects isoforms containing exon 17) but not by
2 F11 (detects isoforms that lack exon 7) the ~90 kDa
band corresponds to BIN1 isoform 1, often referred to as
the “neuronal BIN1 isoform” (henceforth referred as
BIN1:H). The ~65 kDa BIN1 gray matter isoforms failed
to react with both mAb 2 F11 and 99D, which indicates
that they contain exon 7-encoded residues and lack exon
17-encoded residues.
All three BIN1 antibodies revealed significantly higher
BIN1 levels in the white matter (Fig. 2c and d). Quantification revealed that in comparison to the gray matter,
the white matter overall contains ~3-fold higher levels of
BIN1 (normalized to actin) (p <0.0001 by ANOVA)
(Fig. 2d). The predominant white matter BIN1 isoforms
migrated at ~65-75 kDa and were uniformly detectible
by all three antibodies. This observation suggested that

the white matter BIN1 isoforms, for the most part,
lacked exon 7-encoded residues and contained exon 17encoded residues. In contrast to its selective expression
in the gray matter, BIN1:H isoform was conspicuously
absent in the white matter. Our detection of lower molecular weight ~65-75 kDa BIN1 isoforms (henceforth
referred as BIN1:L) in the brain are consistent with the
size of the non-neuronal and ubiquitous BIN1 isoforms
lacking the intact CLAP domain (encoded by exons
13–16). To confirm this notion, we performed RT-PCR
analysis of mRNA isolated from human brain using
forward and reverse primers within the exons 12 and 18,
respectively. By sequence analysis of the PCR products, we
identified multiple BIN1 isoforms generated by variable alternate splicing of BIN1 exons 13–16 (Additional file 7:
Figure S3 and Fig. 2e). Finally, for comparison with BIN1
expression, we also assessed the levels of Amphiphysin 1,
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the brain-specific BIN1 homolog [3, 5, 48]. We found that
Amphiphysin 1 is enriched in the gray matter, consistent
with previous studies describing Amphiphysin 1 as the
neuron-specific homolog of BIN1 (Fig. 2c). This finding
supports the idea that Amphiphysin 1 and BIN1:H isoform
differed in their cell type expression when compared to the
BIN1:L isoforms.
Alteration in the levels of BIN1 isoforms in AD

The diversity of the brain BIN1 isoforms and differential
expression of BIN1 isoforms in the gray and white matter raised the question as to the significance of these
findings to AD. To address this issue, we examined
BIN1 levels in tissue samples from individuals with AD
and age-matched controls. In the gray matter samples
from AD cases, we observed a marked decrease in the
levels of BIN1:H isoform, while there was an increase in
the levels of BIN1:L isoforms (Fig. 3a and b). The relative levels of BIN1:L isoform were significantly higher in
the gray matter of AD cases as compared with the
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controls (Fig. 3c). These findings are in agreement with
an AD-associated decrease in the larger BIN1 isoform
and an increase of the smaller BIN1 isoforms in various
regions of the cortex and the hippocampus reported in a
previous study [30]. Unlike the case of increased BIN:L
levels in the gray matter, comparable levels of BIN1:L
levels were found in the white matter samples (Fig. 3a).
We considered the possibility that the apparent ADassociated decrease in BIN1:H isoform could be the
result of an overall neuronal loss in the gray matter.
Therefore, we simultaneously quantified the levels of
Amphiphysin 1 in the samples and normalized the data
to the levels of actin. The results show significant differences in Amphiphysin 1 levels between controls and AD
samples (Fig. 3a and b). Similar to BIN1:H isoform, the
levels of Amphiphysin1 were markedly lower in the gray
matter AD samples in comparison with the controls,
with a high degree of correlation (Pearson r 0.934; p = 0.02).
To extend this observation, we performed a series of immunoblots to quantify the levels of markers of neurons

Fig. 3 AD-associated changes in the levels of BIN1 isoforms. a Immunoblot analysis of BIN1 and Amphiphysin 1 levels in the brain samples from
controls and AD cases. The age of each individual is listed. The blots were simultaneously probed with BIN1 and Amphiphysin 1 antibodies. The
levels of actin were used as the control for loading. Note that the gray and white matter blots were scanned using different conditions to achieve
equivalent signals. b The levels of Amphiphysin 1 and BIN1 isoforms in the gray matter were quantified using the Li-COR system and normalized to the
levels of actin. The relative expression levels of Amphiphysin 1 and BIN1: H (~90 kDa) were plotted as mean ± SEM (n = 5). The statistical significance
was analyzed by ANOVA. c The plot shows the percentage of BIN1:L (~65-75 kDa) isoform relative to all BIN1 isoforms in the gray matter of each tissue
sample. d Pearson r correlation matrix analysis. The levels of multiple cellular markers were quantified as described above and the relative expression
level differences in AD samples relative to the controls were used to generate the correlation matrix. Larger blue-colored circles represent a higher
degree of correlation, and larger red-colored circles represent an inverse correlation. Smaller neutral-colored circles represent a lack of correlation. A color
scale is drawn at the bottom. GM = gray matter; WM = white matter; Amph 1 = Amphiphysin 1
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(CamKII, PSD-95, and Class III β-tubulin), oligodendrocytes (MBP, ASPA), astrocytes (glial fibrillary acidic
protein [GFAP]), and microglia/macrophages (CD45). We
calculated the relative difference in the levels of each
marker protein in AD versus control samples, and then
performed a Pearson correlation matrix analysis to assess
the degree of relationship between the levels of BIN1
isoforms with the cell-type markers (Fig. 3d). The results
show a significant correlation between BIN1:H and
Amphiphysin 1 with neuronal markers in their relative expression level differences between controls and AD cases.
In contrast, BIN1:L isoforms showed an inverse correlation with neuronal markers. Moreover, AD-associated
changes in the levels of BIN1:L isoforms in the gray matter showed a high degree of correlation with the oligodendrocyte marker ASPA (Pearson r 0.897; p < 0.05).
Significant correlation was also observed between the
levels of BIN1:L isoforms and GFAP in the white matter
(Pearson r 0.936; p < 0.02). Taken together, the results of
qPCR and quantitative immunoblot analyses suggest neuronal and non-neuronal expression of BIN1, and reveal
that the expression of BIN1 isoforms is differentially
affected in brains of patients with AD.
Predominant white matter localization and
oligodendrocyte expression of BIN1 in the human brain

Whereas BIN1 expression in brain has been previously reported, the cellular profile of BIN1 expression in human
has not been characterized in detail [4, 5, 12, 26, 30]. We
performed immunohistochemical analysis of BIN1 labeling in post-mortem human brain tissue using a panel of
four BIN1 antibodies (Fig. 2a). In hippocampus and parahippocampal gyrus of the human brain, all four antibodies
revealed similar strong immunolabeling of the white
matter and weaker immunolabeling of the gray matter
(Figs. 4a–c and 5a). Within the white matter, BIN1 immunolabeling was found along densely-packed myelinated
fiber tracts and in oligodendrocytes, which display the
“fried egg” appearance commonly observed in nonperfused brain tissue (Fig. 4b and d). In the hippocampus,
intense BIN1 immunolabeling was observed along axons
of the perforant path and the alveus (Fig. 4a and 5a). More
importantly, we observed little BIN1 immunostaining in
neuronal soma within the cortex or the hippocampus.
Instead, in the outer layers of the cortex, strong BIN1
labeling was found in smaller cells with radial morphology
and highly ramified processes and in numerous patchy/
punctate processes (Fig. 4c).
Oligodendrocytes are responsible for axon myelination
in the brain. Based on the intense white matter immunolabeling, we predicted that BIN1 is predominantly expressed
in oligodendrocytes. In order to formally determine the
identity of BIN1-positive cells in the human brain, we performed labeling of adjacent sections with multiple BIN1
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antibodies and specific markers for mature oligodendrocytes, astrocytes, and microglia. Immunolabeling with an
antibody against tubulin polymerisation-promoting protein p25 (TPPP), a marker for mature oligodendrocytes,
revealed a cellular pattern of immunolabeling very similar
to that of BIN1 antibodies in all brain regions studied. For
example, TPPP stained nearly all the cells in the cerebral
peduncle, which contains a large number of myelinating
oligodendrocytes whose processes ensheath the axons that
project to the cerebellum and the spinal cord (Fig. 4d).
Adjacent sections stained with three BIN1 antibodies revealed intense labeling of the fiber tracts and labeling of
the oligodendrocyte cell bodies within the cerebral peduncle. In contrast, BIN1 immunolabeling of oligodendrocytes and their fine processes in the CA1 region, as well as
the intense immunolabeling of fiber tracks in the alveus,
were strikingly distinct from the evenly dispersed Ionized
calcium-binding adapter molecule 1 (Iba1) and GFAP
immunolabeling of microglia and astrocytes, respectively
(Fig. 4e). The predominant oligodendrocyte cell-type
immunolabeling of BIN1 is also discernable based on a
comparison of the structure of the stained population of
cells, each with their distinctive cellular morphology
(Fig. 4f). In order to determine more precisely the
localization of BIN1 in myelinated axons, we performed
two-color immunostaining with antibodies against BIN1
and Caspr (Contactin-associated protein), an axonal membrane protein. In comparison to Caspr, which becomes
concentrated in the paranodal junctions of myelinated
axons [49], BIN1 displayed patchy distribution along short
segments of interdigitating processes without an apparent
concentration in the nodes or the paranodal area (Fig. 4g).
Moreover, we also observed annular immunolabeling of
BIN1, which likely represent cross-sections of traversing
myelinated axons. Together, these results show predominant oligodendrocyte expression and white matter
localization of BIN1 in the human brain.
Cell-type specific expression and complementary
localization of BIN1 and Amphiphysin 1

The findings detailed above were surprising because it is
generally assumed, and in a few papers described, that
BIN1 is expressed in neurons [4, 26, 30]. In order to carefully assess the distribution of BIN1 in the human brain,
we performed immunohistochemical analysis of BIN1 and
compared it to the distribution of Amphiphysin 1. Strikingly, adjacent sections stained with antibodies against
Amphiphysin 1 and BIN1 revealed a near complementary
pattern of expression in the cortex, hippocampal CA
fields, hilus, subiculum, fimbria, caudate nucleus, lateral
geniculate nucleus, and cerebral peduncle (Fig. 5a).
Amphiphysin 1 was widely expressed in neurons throughout the cortex and hippocampus. Notably, Amphiphysin 1
immunolabeling was apparent in neuronal soma and was
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Fig. 4 White matter localization and oligodendrocyte expression of BIN1 in the human brain. a Immunohistochemical staining of the hippocampus
and parahippocampal gyrus using goat pAb N-19 (top) and mAb 2 F11 (bottom) reveal prominent white matter labeling. In the hippocampus, the
perforant path axons and the alveus are labeled. b Higher magnification images of N-19 shows relatively weaker labeling in the cortex and intense
labeling in the white matter. Note the labeling of mature oligodendrocytes (white arrows) in the enlarged area. c Higher magnification of mAb 2 F11
labeling reveals intense BIN1 labeling of smaller cells with a radial morphology and ramified processes (red arrows), and only a weak labeling of larger
neuronal cell bodies (black arrows). In addition punctate and discontinuous staining along fine linear processes is also visible. d TPPP immunolabeling
identifies mature oligodendrocytes in cerebral peduncle (red arrows). Analysis of adjacent serial sections reveal BIN1 labeling of mature oligodendrocytes
and traversing myelinated fibers. e, f Immunohistochemical analysis of adjacent sections of hippocampal CA1 region reveals that the BIN1 cellular labeling
pattern is distinct from that of microglia (Iba1) and astrocytes (GFAP). g Two-color immunostaining of BIN1 and Caspr. The inset shows a magnified area
where the localization of BIN1 (brown) and Caspr (red) along adjacent segments of the axon tracts can be seen. BIN1 immunolabeling of annular
structures likely represents cross sections of myelinated axons that lie perpendicular to the plane of the section. WM = white matter; Alv = alveus;
Hipp = hippocampus; EC = entorhinal cortex; F = fimbria; DG = dentate gyrus; Sub = subiculum; PP = perforant path; CA1 = Cornu Ammonis area 1
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Fig. 5 Distinct cellular localization of BIN1 and Amphiphysin 1 in the human brain. a Immunohistochemical labeling of adjacent sections of the
hippocampus and parahippocampal gyrus using mAb against Amphiphysin 1 or BIN1 (99D) reveals near complementary pattern of labeling.
Amphiphysin 1 antibody does not stain the white matter whereas intense BIN1 labeling is observed in the white matter. b Amphiphysin 1 and
BIN1 immunolabeling of the cortex (the boxed area in panel A) and a section of the white matter are shown at a higher magnification. Boxed regions
in the external granule layer and internal pyramidal layer are also shown at further magnification to visualize the cells that are immunoreactive.
Amphiphysin 1 and BIN1 labeling of morphologically distinct neurons and oligodendrocytes, respectively, are quite obvious. c Amphiphysin 1 and
BIN1 labeling of the hippocampal area. A higher magnification of the boxed area of CA2 and dentate gyrus is shown at the bottom and on the right,
respectively. In all areas, Amphiphysin 1 mAb stains the neuronal soma and the neuropil whereas BIN1 mAb stains smaller cells and profuse branched
processes. Very little BIN1 signal is found in neurons. Amphiphysin 1 but not BIN1 localizes to the terminal fields of hippocampal mossy fibers, which
are non-myelinated. Amph 1 = Amphiphysin 1; WM = white matter; Alv = alveus; Hipp = hippocampus; Sub = subiculum; EC = entorhinal cortex;
CA = caudate nucleus; CP = cerebral peduncle; F = fimbria; LGN = lateral geniculate nucleus; EGL = external granular layer; IPyL = internal pyramidal
layer; DG = dentate gyrus; CA2-CA4 = Cornu Ammonis areas 2–4; MF = mossy fibers; PML = polymorphic layer; GCL = granule cell layer; ML = molecular
layer; SO = stratum oriens; SP = stratum pyramidale; SR = stratum raidatum
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also intense in the neuropil (Fig. 5b and c). In comparison,
we observed little, if any, neuronal or neuropil BIN1
immunolabeling in the cortex or hippocampus (Fig. 5b
and c). On the contrary, BIN1 immunolabeling showed a
strong signal in the white matter. Interestingly, whereas
Amphiphysin 1 antibody labeled the mossy fiber terminal
field in the hippocampus, these unmyelinated axons of the
dentate gyrus granule cells are not labeled by the BIN1
antibody (Fig. 5c). Similarly, the Amphiphysin 1 antibody
labeled the terminal zones of the associational and commissural pathways, as well as the perforant pathway in the
molecular layer of the dentate gyrus, whereas BIN1 immunolabeling in this area was restricted to a few ramified
cells and their processes (Fig. 5c). Thus, immunohistochemical staining and immunoblot analysis with independent antibodies support the assertion that BIN1 is
enriched in the human brain white matter and shows little
overlap with the expression and neuronal localization of
its close homolog Amphiphysin 1.
BIN1 expression in mature oligodendrocytes and
localization in the white matter tracts in rodent brain

In order to ascertain the cellular distribution of BIN1,
we performed immunofluorescence labeling of mouse
and rat brain tissue. Labeling with three BIN1 antibodies
revealed striking localization of BIN1 in the corpus callosum (Fig. 6a and b, and Additional file 8: Figure S4).
In the cortex, BIN1 immunolabeling was observed in the
soma of numerous cells dispersed in all cortical layers
(Fig. 6c). Within the corpus callosum, the BIN1 antibodies stained linear arrays of cells characteristic of
interfascicular oligodendrocytes (Fig. 6b and Additional
file 8: Figure S4C and D). In addition to the arciform
BIN1 immunolabeling of the soma, punctate BIN1
immunolabeling was apparent in the cortex along the
processes with short barbed branches and in the white
matter along parallel oriented tracks, as visualized by
high-resolution confocal microscopy (Fig. 6b). Doubleimmunofluorescence labeling analysis revealed that
BIN1 immunolabeling essentially overlapped with MBP
localization in the corpus callosum (Fig. 6a), in corticostriatal projections (Fig. 6d) and in the cerebellar white
matter (Fig. 6e). In contrast to the intense NeuN labeling
of the hippocampal neurons, BIN1 labeling was not
readily discernable (Fig. 6a and f ). Instead, BIN1 immunolabeling was observed in a few smaller cells and fine
processes in the hippocampus. Similarly, easily distinguishable large neurons in striatum stained positive for
Amphiphysin 1, whereas BIN1 localized to smaller cells
and intersecting myelinated fiber bundles consistent
with prominent non-neuronal BIN1 expression (Fig. 6g).
Examination of BIN1 and Amphiphysin 1 distribution
in the cerebellum revealed the most intense BIN1 labeling in the white matter, whereas Amphiphysin labeling
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was present in the molecular layer along with synaptophysin (Fig. 7a and b). Within the granule cell layer,
BIN1 immunolabeling was mainly found in processes,
which were in close proximity to synaptophysin-positive
glomeruli (multisynaptic agglomerations of mossy fiber
terminals), but essentially with little overlap as revealed
by line scan analysis (Fig. 7c). A comparison of the distribution of BIN1 with the paranodal marker Caspr in
the cortex and the hippocampus revealed that BIN1 localized to discontinuous segments along slender processes adjacent to Caspr, with little or no overlap
(Fig. 7d), suggesting its localization to the internode sections. The results described above provide compelling
evidence for the paucity of BIN1 in neurons and its enrichment in the white matter tracts in rodent brain mirroring our observations in the human brain.
Finally, BIN1-positive cells in the cortex and corpus
callosum were positive for ASPA, TPPP, and CC1 epitope, markers for mature oligodendrocytes (Fig. 7e and f,
and data not shown). Immunolabeling using an antibody
against neural/glial antigen 2 (NG2) showed little or no
expression of BIN1 in oligodendrocyte progenitor cells
(Fig. 7g and h). Similarly, BIN1 was not expressed in
microglia or astrocytes (Fig. 7i and j). BIN1 was not detected at appreciable levels in dendrites (identified by
microtubule-associated protein 2 [MAP2] labeling) or
presynaptic sites (synapsin 1 labeling) in the cortex (data
not shown). As expected from BIN1 localization in myelinating oligodendrocytes, BIN1 immunolabeling showed
overlap with the axonal marker phospho-neurofilament
(data not shown). Together, the results described above
are consistent with high-level BIN1 expression in mature
oligodendrocytes and their processes in the brain.
Upregulation of BIN1 during developmental myelination
and oligodendrocyte maturation

Myelin formation in the rodent brain begins in the first
postnatal week and peak myelination occurs 2–3 weeks
after birth. In order to characterize BIN1 expression during this period, we analyzed BIN1 expression in post-natal
rat brain at 7 days, 15 days and 21 days. Multiple alternatively spliced BIN1 isoforms in the range of ~ 55–115 kDa
were detectible using pAb BSH3 (Fig. 8a). Quantitative
immunoblot analysis revealed a significant increase in all
BIN1 isoforms during the post-natal period of oligodendrocyte generation and intense myelination (p < 0.01).
Furthermore, following the initial increase, high-level
BIN1 expression was maintained in the adult rodent brain
(Fig. 8c). Moreover, like in the human brain BIN1:L isoforms were relatively more abundant than the BIN1:H isoform, which is presumably expressed in neurons. To
confirm these results, we assessed BIN1 expression during
in vitro differentiation of cultured rat oligodendrocyte
progenitor cells isolated from rat brain. Immunoblot
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Fig. 6 The distribution of BIN1 in mouse brain. BIN1 immunolabeling is in green and the marker labeling is in red. Nuclear staining with Hoechst
is in blue. a Immunofluorescence labeling of coronal sections with antibodies against BIN1 (N-19 or BSH3) shows overlap with MBP but not with
NeuN labeling. b–g Confocal microscopy analysis of BIN1 immunolabeling. b A low magnification image of BIN1 labeling with mAb 2 F11. A
higher magnification of the cortex and corpus callosum is shown in the middle and right panels. Thick and thin arrows point to BIN1 labeling of
the cell body and barbarized processes in the cortex. c N-19 labeling reveals BIN1-positive cells dispersed throughout the cortical layers. d and e
BIN1 and MBP labeling overlap along corticostriatal projections and in the cerebellar white matter. f BIN1 and NeuN labeling are largely distinct in
the hippocampus and striatum. BIN1-positive cell bodies (white arrows) and processes in stratum oriens or fiber bundles in alveus (yellow arrows) are
indicated. g BIN1 immunolabeling of cell bodies (white arrows) and fiber bundles (yellow arrows) in the striatum does not overlap with neuronal and
neuropil labeling of Amphiphysin 1. CC = corpus callosum; CA1 = Cornu Ammonis area 1; SO = stratum oriens; SP = stratum pyramidale

analysis revealed a significant upregulation of BIN1 levels,
specifically BIN1:L isoforms, during oligodendrocyte maturation (Fig. 8b). In parallel, we assessed BIN1 expression
in cultured neurons following in vitro differentiation for
21 days and found that BIN1 expression was only weakly
detectable in mature neurons. In contrast, Amphiphysin 1

was expressed at high levels in mature neurons but not in
cultured oligodendrocytes (Fig. 8b). These findings corroborated previous studies that reported high levels of
Bin1 transcripts in mature oligodendrocytes [32, 45] and
are entirely in agreement with our in vivo localization of
BIN1 and Amphiphysin 1 in mature oligodendrocytes and
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Fig. 7 Expression of BIN1 in mature oligodendrocytes. BIN1 immunolabeling is in green and the marker labeling is in red. Nuclear staining with
Hoechst is in blue. a-c Sagittal sections of the cerebellum were labeled with the indicated antibodies. BIN1 labeling is prominent in the white
matter whereas no labeling for Amphiphysin was observed in the white matter. Synaptophysin and Amphiphysin 1 labeling are prominent in the
molecular layer synaptic terminals and in the granule cell layer mossy fibers. Higher magnification of the granule cell layer reveals BIN1-positive
processes (arrows) around synaptophysin-positive mossy fibers c. The areas indicated by the rectangles are enlarged on the right. Line-scan analysis of
BIN1 and synaptophysin fluorescence intensities plotted as graphs shows that the proteins localize to distinct structures. d BIN1 labeling in the cortex
is found along the internodal segments of processes (arrows) adjacent to the paranodal localization of Caspr. e and f All BIN1-positive cells (arrows)
are also positive for ASPA and TPPP, which are markers of mature oligodendrocytes. A higher magnification of the boxed areas is shown. g–j BIN
labeling in cortex and corpus callosum (white arrows) does not overlap with NG2-labeled OPCs, Iba1-labeled microglia or GFAP-labeled astrocytes
(yellow arrows). Syn = synaptophysin; Amph 1 = Amphiphysin 1; WM = white matter; ML = molecular layer; GCL = granule cell layer; CC = corpus callosum;
CB = cingulum bundle
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Fig. 8 Immunoblot analysis of BIN1 expression in rodent brain and cultured oligodendrocytes. a The post-natal increase in BIN1 expression. Immunoblots
of brain lysates from the indicated developmental periods were analyzed by Western blots using the indicated antibodies. The levels of flotillin 2 and
actin were assessed as loading controls. The graph represents quantification of BIN1 signal intensities normalized to actin. b The increase of BIN1
expression during in vitro oligodendrocyte differentiation. Lysates of cultured rat OPCs, mature oligodendrocytes (OL) following 3 or 5 days
of differentiation, mature neurons, and astrocytes were analyzed by immunoblots. The levels of MBP, CamKII, and GFAP were analyzed as markers
for mature oligodendrocytes, neurons, and astrocytes, respectively. BIN1 is highly expressed in mature oligodendrocytes whereas Amphiphysin 1 is
abundant in mature neurons. The graph represents quantification of BIN1 signal intensities normalized to actin. c Enrichment of BIN1:L in the corpus
callosum. Adult rat brain was microdissected into different regions and homogenates were analyzed by immunoblotting using BSH3 and cellular
marker antibodies. Amph 1 = Amphiphysin 1

neurons, respectively, by immunohistochemical staining.
Finally, we analyzed BIN1 isoform expression by dissecting different regions of adult rat brain. From this analysis,
it became clear that BIN1:L isoforms were uniquely
enriched in the corpus callosum (Fig. 8c), consistent with
the results from human brain white matter.
Loss of BIN1 immunolabeling in demyelinated plaques of
patients with multiple sclerosis

The results outlined above showing expression of BIN1
in the myelin tracts prompted us to examine BIN1
immunolabeling in the brains of individuals with multiple sclerosis, as a disease model for demyelination. In a
pilot study, we performed BIN1 labeling of autopsy brain
samples from a set of confirmed cases of multiple sclerosis and compared the results to the staining of Luxol

fast blue, a commonly used myelin stain. Fig. 9a shows
Luxol fast blue staining of an inactive/chronic multiple
sclerosis plaque, revealing a well-demarcated area of
hypocellularity with myelin pallor. An adjacent serial
section stained with BIN1 antibody reveals the loss of
BIN1 immunolabeling within the lesion relative to an intense periplaque normal white matter labeling (Fig. 9a).
We also analyzed the similarities in Luxol fast blue and
BIN1 staining intensities in active multiple sclerosis plaques with demyelination and activated macrophages,
and in shadow plaques where the axons maintain uniformly thin myelin sheaths. The results from three BIN1
antibodies reveal the high degree of similarity between
BIN1 labeling intensity and the extent of myelin loss in
multiple sclerosis lesions (Fig. 9b and Additional file 9:
Figure S5). BIN1 immunolabeling in shadow plaques
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Fig. 9 Loss of BIN1 parallels myelin loss in multiple sclerosis brain lesions. a Staining of adjacent serial autopsy brain sections with Luxol fast blue
(left) and BIN1 antibody (right) shows myelin loss that parallels striking loss of BIN1 labeling intensity within a chronic/inactive multiple sclerosis
plaque. b Adjacent sections of samples from multiple sclerosis patients were analyzed by histology or immunohistochemistry. Images correspond
to an active lesion (top), shadow plaque (middle) and chronic plaque (bottom). Dashed lines mark the lesion border. c Luxol fast blue (not shown)
and BIN1 antibody staining intensities were quantified from digitized images. The percentage difference in the staining intensities within lesions in
comparison to adjacent normal white matter was calculated. Correlation matrix analysis reveals a significant correlation between myelin loss and
reduction in BIN1 immunolabeling intensities. d Higher magnification of the border of an active lesion depicting myelin fragmentation and loss of
BIN1 immunoreactivity. CD68 staining of foamy macrophages (arrows) and GFAP staining of hypertrophic astrocytes (asterisks) are also shown in the
bottom panels. NWM = normal white matter

was more intense in comparison to chronic plaques,
consistent with remyelination in these lesions. In all
cases, BIN1 immunolabeling appeared to be restricted to
cells with oligodendrocyte morphology. Notably, BIN1

immunolabeling was not detectable in CD45-positive
perivascular cells (Additional file 10: Figure S6B), or in
CD68-positive foamy macrophages and GFAP-positive
reactive astrocytes located in the periphery of the active
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lesions (Fig. 9d). Correlation matrix analysis, comparing
the intensity difference of Luxol blue staining or BIN1
antibody labeling within the lesion relative to the periplaque region, revealed a significant correlation between
the loss of myelin and the decrease of BIN1 immunolabeling (Fig. 9c). The diminution of BIN1 within chronic
lesions and its reemergence during remyelination within
the multiple sclerosis lesions are consistent with BIN1
expression in myelinating oligodendrocytes.

Discussion
In this paper, we document prominent BIN1 expression
in mature oligodendrocytes and its localization within
the white matter in the brain, which strikingly contrasts
with neuronal and presynaptic localization of the BIN1
paralog, Amphiphysin 1. Our study reveals the upregulation of BIN1 expression during in vivo myelination as
well as oligodendrocyte maturation in vitro. Moreover,
we reveal the diversity of brain BIN1 isoforms and report on the alteration of select BIN1 isoform expression
in patients with AD. Finally, we show that the loss of
BIN1 immunoreactivity closely parallels myelin loss
within brain lesions of individuals with multiple sclerosis
in a pilot study. Altogether, our findings bring clarity to
the issue of BIN1 expression and isoform diversity in the
brain and provide novel insights on a possible nonneuronal role for BIN1, which has been genetically characterized as the second most significant risk factor for
late-onset AD.
Predominant oligodendrocyte expression of BIN1

Previous studies have reported conflicting descriptions of
BIN1 expression and localization in the brain. An earlier
study characterized BIN1 by fractionation and immunolocalization and reported that BIN1 was enriched in nerve
terminals in a manner similar to Amphiphysin 1 [5].
Concurrently, another study reported distinct localization
of BIN1 in initial axon segments and nodes of Ranvier,
with no overlap with the punctate nerve terminal immunolabeling of Amphiphysin 1 [4]. These differences likely
resulted from the utilization of isoform-specific BIN1 antibodies. Using a large panel of antibodies, our results from
immunohistochemical analyses of adjacent human brain
sections for BIN1 and Amphiphysin 1 provides compelling
evidence that these homologs are expressed in distinct cell
types (Fig. 5). These findings were confirmed with detailed
confocal microscopy analysis of BIN1 expression in rodent
brain (Table 2). Overall, the results reveal that BIN1 is
predominantly expressed in mature oligodendrocytes and
highly enriched in the white matter in rodent and the human brain. Immunoblot analysis of human and rat brain
tissue reveals that the neuronal BIN1:H isoform is
expressed at lower levels only in the gray matter as compared with the more abundant BIN1:L isoforms, which
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are expressed in both the gray matter and white matter.
Entirely consistent with our findings, BIN1 was one of the
308 proteins identified in both human and mouse brain
myelin preparations by mass spectrometry [50].
Previous studies using the same antibodies employed
in our analysis identified similar immunolabeling in the
human brain as reported here, but attributed the labeling to neuronal soma or nucleus without comparing
BIN1 immunolabeling with markers for neurons or oligodendrocytes [13, 26, 30]. Our results clearly show that,
unlike Amphiphysin 1, the large majority of BIN1 immunoreactivity is not associated with neurons in the human
brain (Fig. 5). In addition, it is clear that very little overlap exists between the cellular immunolabeling of NeuN
and BIN1 throughout the rodent brain. Mature oligodendrocyte expression of BIN1 was established in our experiments using three commonly used cellular markers of
oligodendrocytes. While our results are in agreement with
a previous study reporting presynaptic localization of
Amphiphysin 1 resembling that of synaptophysin in the
cerebellum [3], they reveal that BIN1 localization markedly differs from that of synaptophysin. Specifically, BIN1
is highly enriched in white matter tracts in the cerebellum
where it overlaps with MBP; in contrast synaptophysin
and Amphiphysin 1 do not localize to the white matter
(Figs. 5 and 6).
Although BIN1 mRNA expression in microglia acutelyisolated from mouse brain was observed in RNA-seq experiments [45], our results show little evidence in support
of microglial localization of BIN1 at the protein level in
the human or mouse brain. Similar to our findings, no
overlap in the cellular expression of BIN1 and Iba1 was
observed in the hippocampus of patients with AD [26].
Furthermore, our study reveals BIN1 immunolabeling of
morphologically distinct cell types from those stained by
Iba1, CD45, and CD68, arguing against detectable levels
of BIN1 expression in mouse or human brain microglia or
macrophages in situ (Figs. 3, 6, 8, and Additional file 10:
Figure S6). These findings are summarized in Table 2.
The significance of BIN1 expression in oligodendrocytes

High-level BIN1 protein expression in mature oligodendrocytes and the white matter in our studies are in
agreement with the Barres lab’s identification of Bin1
among the top 50 highly expressed genes in cultured oligodendrocytes in a microarray study [32], and proteomic
identification of BIN1 in human and mouse brain myelin
preparations [50]. Our results show an increase of BIN1
levels both during oligodendrocyte maturation in vitro
and critical period of myelination in vivo. Upregulation
of BIN1 during synchronous differentiation of cultured
oligodendrocytes is consistent with earlier microarray
and recent RNAseq datasets [32, 45]. Similarly, a significant decrease in BIN1 expression was observed in
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Table 2 Summary of BIN1 expression in the brain analysed using cellular markers
Markers
Brain tissue

Neurons

Mature

Immature

Microglia

Astrocytes

Macrophages

Oligodendrocytes
NeuN, Amph 1, Calbindin, Parvalbumin

ASPA, TPP25, CNPase, CC1

NG2

Iba1, CD45

GFAP

CD68

Mouse/rat

−

++++

−

−

−

−

Human

−

++++

ND

−

−

−

The cellular markers employed to determine BIN1 expression in different cell types are indicated. ++++ = strong expression; − = no expression; +/− weak or
occasional expression; ND not determined

microarray analysis of multiple sclerosis brain lesions in
comparison with control brain samples (GEO DataSet
GDS4218) [51]. In agreement, our analysis of brain tissue from patients with multiple sclerosis shows a close
correlation between BIN1 levels and the intensity of
myelin labeling across the different types of lesions. Notably, BIN1 labeling within the shadow plaques indicates
possible reemergence of BIN1 expression during remyelination. Thus, BIN1 upregulation during oligodendrocyte maturation and its localization to myelinating
oligodendrocytes have potential implications not only
for normal physiology in the healthy brain but also for
myelin repair under pathological conditions. OPCs remain abundant in the adult brain as lineage-restricted
cells, which retain their capacity to proliferate and mature into myelinating oligodendrocytes as needed in response to demyelination resulting from injury or disease
conditions. The lack of BIN1 expression in NG2-positive
OPCs and the coordinate upregulation of BIN1 along
with myelin-specific proteins suggest a possible role for
BIN1 in membrane remodeling that accompanies the
transition from the progenitors into myelinating oligodendrocytes with long arborized processes.
BIN1 isoform diversity in the brain

We report two important insights based on the results
of our immunohistochemistry and immunoblot analyses.
First, BIN1 levels are enriched in the human white matter in comparison to the gray matter. This finding is in
agreement with the comparison of BIN1 transcript levels
between the human white matter and the gray matter reported from independent microarray analyses [50, 52, 53].
Second, the isoform distribution of BIN1 between the gray
matter and white matter differs significantly, as revealed
by different BIN1 antibodies. The ~90 kDa BIN1 isoform
is expressed only in the gray matter at lower levels,
whereas the ~65-75 kDa BIN1 isoforms are the predominant forms in the gray matter and white matter. Expression
of seven brain-specific and two ubiquitous BIN1 isoforms
have been reported previously [4, 6, 7]. Consistent with
the previous characterization that the neuronal BIN1
isoform 1 contains the intact CLAP domain responsible
for binding to clathrin, we clearly see an enrichment of
the ~90 kDa BIN1 (the largest BIN1 isoform in the brain)
in the gray matter. However, it is somewhat surprising that

the BIN1 isoform 1 is not the predominant BIN1 species in
the human brain. Our immunoblot analysis of controls and
AD patients revealed that the majority of BIN1 isoforms
expressed in the brain corresponded to ~65-75 kDa, the
reported size of the ubiquitous BIN1 isoforms, raising the
possibility that they may lack the CLAP domain.
By direct sequencing of the human brain RT-PCR
products, we have confirmed variable alternate splicing
of BIN1 exons 13–16, which encodes the CLAP domain
(Additional file 7: Figure S3). Thus, the results from immunoblot and RT-PCR analysis show that several human
brain BIN1 isoforms lack the CLAP domain, entirely or
at least partially. Our findings are similar to the previously reported RT-PCR analysis of BIN1 isoform composition in rat brain and peripheral tissue [7]. Since the
CLAP domain is required for BIN1 interaction with clathrin, these observations raise the possibility that large
proportion of BIN1 expressed in the brain may not participate in clathrin-mediated endocytosis [54]. Evidence
from the analysis of Drosophila Amphiphysin, encoded
by the unique Amphiphysin gene (and thought to be a
BIN1 ortholog), show that absence of the CLAP domain
results in no detectable defects in synaptic vesicle endocytosis in mutant flies [55–57]. Thus, the precise cellular
functions of the major BIN1 isoforms in the brain remain to be established.
BIN1 expression in the brains of patients with AD

The functional connection between BIN1 and the susceptibility to AD remains to be elucidated. Initial attempts to determine whether BIN1 expression might be
altered in AD have resulted in discordant findings.
While two studies have reported significantly increased
BIN1 transcripts levels in brains of individuals with AD
[26, 31], another found a positive correlation between
BIN1 expression levels and later age at onset of the disease [28]. Apparent disagreements were also reported by
immunoblot analysis of BIN1 expression in individuals
with AD. Whereas, a significant decrease in BIN1 levels
was observed by immunoblot analysis in one study [29],
an increase in BIN1 levels was reported in another study
[30]. A comparison of the findings from these two reports with the results of our study offers some clarity to
this apparent discrepancy. Uniformly, all three studies
report a decrease of the ~90 kDa BIN1:H isoform and
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an increase of the ~65-75 kDa BIN1:L isoforms (Fig. 3).
Further, we show that the decrease of the BIN1:H isoform correlated with a decrease in Amphiphysin 1 and
neuronal markers, concurrent with the loss of neurons
observed in AD. While BIN1:L expression highly correlated with oligodendrocyte markers, as expected from
our immunostaining analysis, the correlation with GFAP
or CD45 could also suggest an increase in BIN1:L expression in parallel with activation of astrocytes and
microglia as well as infiltration of macrophages during
pathogenesis. While this manuscript was under review,
Adams and colleagues reported BIN1 expression in
white matter and oligodendrocytes in the brain but not
in neurons in healthy controls [58], consistent with our
results. Interestingly, their study revealed weak BIN1 immunoreactivity in a subset of neurons in patients with
AD. The findings described here complement the report
by Adams et al. by identifying selective alterations of
BIN1 isoforms in the gray matter of patients with AD.
A potential function for BIN1 in AD pathogenesis

There is substantial interest in understanding the functional connection between BIN1 and AD pathogenesis. In
an earlier study, RNAi-mediated silencing of BIN1 expression in HeLa cells resulted in a 1.5- and 2-fold increase in
Aβ40 and Aβ42 secretion, respectively [59]. It is tempting
to speculate that this effect could have resulted from alterations in proteolytic processing of APP in endosomes in
cells lacking BIN1 expression. However, the lack of a significant change in sAPPβ production argues against a simple model whereby the loss of BIN1 had an effect on
endocytic trafficking of APP or BACE1, thus promoting
amyloidogenic processing of APP. Moreover, the loss of
BIN1 function neither impaired endocytic transferrin uptake in Bin1−/− fibroblasts nor phagocytic internalization
of zymosan [10]. Thus, it is unlikely that RNAi knockdown
of BIN1 introduced endocytic defects that altered Aβ generation. Interestingly, partial or total loss of Amphiphysin
expression attenuated the rough eye phenotype induced by
the overexpression of human Tau but not Aβ42 in
Drosophila eye. A previous study showed an interaction
between fly Amphiphysin and human Tau in a fly model of
AD Tau pathology [26]. Whether this functional interaction between BIN1 and Tau enhances AD risk in mammalian brain awaits experimental confirmation. In this
regard, it is worth noting that Tau is expressed in mature
oligodendrocytes and Tau recruitment to the sites of
process outgrowth is a critical step in the initiation of myelination [60, 61]. Whether a functional interaction between
BIN1 and Tau in oligodendrocytes has physiological and/
or pathological implications in myelination is a topic worth
investigating in the future.
AD pathology in the white matter includes the loss of
myelin and a decrease in oligodendrocyte proteins [62–68].
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The exposure of oligodendrocytes to Aβ induces apoptotic
cell death [69] and studies in AD transgenic mouse models
show defects in myelin integrity [70, 71]. Moreover, analysis of human post-mortem brain tissue suggests an agerelated reduction in myelin repair capacity associated with
AD pathogenesis [71]. Therefore, insights into BIN1’s function in oligodendrocytes will advance our understanding of
its involvement as an AD risk factor.

Conclusions
BIN1 is the most significant late-onset AD susceptibility
locus identified via the genome-wide association studies.
Multiple BIN1 isoforms are expressed in the human brain
and there are significant changes in the levels of select BIN1
isoforms in the brains of individuals with late-onset AD.
BIN1 is predominantly expressed by the myelinating cells in
the brain and its expression is upregulated during myelin
formation in vitro and in vivo. BIN is enriched in the white
matter in the human and rodent brain and its diminution
correlates with the extent of demyelination within subcortical plaques of patients with Multiple Sclerosis. Our results
suggest a potential role for BIN1 in mature oligodendrocytes
in the brain.
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Additional file 1: Table S1. List of antibodies used in this study.
(DOCX 108 kb)
Additional file 2: Figure S1. Quantification of BIN1 transcript levels in
the brains of patients with and without Alzheimer’s disease. (A-C) Scatter
plots of BIN1+Ex7 expression in comparison with cellular marker expression.
(D-F) Scatter plots of D7-Ex7 expression in comparison with cellular marker
expression. AD = Alzheimer’s disease; Norm = normalized expression. The
results do not support an association between BIN1 expression and the
expression of cellular markers of astrocytes (GFAP), microglia [geometric
mean of CD11b (ITGAM) and Iba1 (AIF1) expression (Malik et al., 2013)], and
endothelial cells [geometric mean of von Willebrand Factor (VWF) and
CD31 (PECAM1) expression (Parikh et al., 2014). (TIFF 362 kb)
Additional file 3: Table S2. BIN1+ Ex7 expression is correlated with AD
status and synaptophysin expression. (DOCX 15 kb)
Additional file 4: Table S3. Quantification of BIN1+Ex7 expression
relative to AD status. (DOCX 44 kb)
Additional file 5: Table S4. D7-BIN1 expression is correlated with MBP
expression but not AD status (DOCX 37 kb)
Additional file 6: Figure S2. Characterization of polyclonal BIN1
antibody BSH3. (A) Schematic illustration of the exon structure of BIN1
and possible alternate splicing. The protein structures of BIN1 isoforms
6-10 generated by alternate splicing of exons 13-17, which encode the
CLAP and MBD are depicted. Note that exons 18-20 are invariable in all
BIN1 isoforms. (B) Immunoblot analysis of C-terminally FLAG-tagged BIN1
isoforms 6-10 expressed in HEK293 cells [expression plasmids were
generously provided by Dr. Zhou, Merck Research Laboratories]. Blots
were probed with pAb BSH3 or anti-FLAG mAb. BSH3 was raised against
residues encoded by exons 17-20. The results show that BSH3 is capable
of reacting with isoform 10, which lacks exon 17 encoded residues. Thus,
this antibody reacts with epitopes common to all BIN1 isoforms, encoded
by exons 18-20. N = NH2 terminus; BAR = Bin-amphiphysin-Rvs domain;
PI = phosphoinositide binding domain; CLAP = clathrin/Adaptor protein
2 binding domain; MBD = MYC-binding domain; SH3 = SRC homology 3
domain. (C) Immunofluorescence analysis of antibody specificity. HEK293
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cells transiently transfected with FLAG-tagged human BIN1 isoform 7
were stained with a combination of antibodies against the FLAG epitope
tag or the indicated BIN1 antibodies. Wide-field images acquired on a
Nikon TE2000 microscope using a 100X objective reveal that each BIN1
antibody strongly stains transfected cells. (TIF 1481 kb)
Additional file 7: Figure S3. Identification of human brain BIN1 isoforms.
(A) Schematic illustration of the exon structure of BIN1 and possible alternate
splicing. (B) Analysis of human brain RT-PCR products. Human brain samples
were subjected to RT-PCR analysis by using primers corresponding to
sequences within exons 12 and 18 and the resulting amplicons were
separated by polyacrylamide gel electrophoresis. Individual bands were
excised from the gels and analyzed by sequencing to identify the major
isoforms generated by alternate splicing of exons 13-17. The relative amounts
of the isoforms within samples are semi-quantitative given that the smaller
PCR amplicons could have been preferentially amplified as these samples
underwent 30 cycles of PCR amplification. (TIF 271 kb)
Additional file 8: Figure S4. The distribution of BIN1 in rat brain. BIN1
staining is in green and nuclei stained with Hoechst are in blue. (A and B)
Immunofluorescence staining of coronal sections with antibodies N-19 or
2F11 reveals BIN1 immunoreactivity in the cortex with intense straining of
the corpus callosum (CC). (C and D) Higher magnification images of 2F11
staining of oligodendrocytes dispersed in the cortex and arranged as linear
arrays in the corpus callosum. (TIFF 5477 kb)
Additional file 9: Figure S5. Loss of BIN1 staining in multiple sclerosis
brain lesions. Staining of adjacent serial autopsy brain sections with Luxol
fast blue (left) and BIN1 antibodies N19 and 99D shows that myelin loss
parallels the loss of BIN1 staining intensity within multiple sclerosis plaques.
Images correspond to an active lesion (top), shadow plaque (middle) and
chronic plaque (bottom). Dashed lines mark the lesion border. (TIFF 9463 kb)
Additional file 10: Figure S6. BIN1 is not expressed in human brain
microglial cells. (A) Immunohistochemical staining of adjacent sections of
normal human brain cortex with antibodies against BIN1 or Iba1 reveals
that BIN1 immunoreactive cells that are morphologically distinct from
microglia. The boxed region is shown at a higher magnification on the
right. (B) Single and two-color immunostaining of the human brain using
antibodies against BIN1 and CD45 reveals that perivenular CD45-positive
cells of the hematopoietic lineage do not express BIN1. (TIFF 4392 kb)
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